FIELD: medicine.
SUBSTANCE: invention relates to methods of treating a human suffering or susceptible to C3-glomerulopathy, comprising administering to a human an effective amount of a C5aR antagonist.
EFFECT: method of treating C3-glomerulopathy is proposed.
32 cl, 2 ex, 2 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | 2010 |
|
RU2607635C2 |
| HUMAN CYTOCHROME 11B2 INHIBITORS | 2022 |
|
RU2800378C1 |
| NOVEL BICYCLIC DERIVATIVES | 2020 |
|
RU2830113C2 |
| NOVEL ISOQUINOLINE DERIVATIVES | 2020 |
|
RU2839897C2 |
| 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND USE THEREOF AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E-SYNTHASE INHIBITORS | 2015 |
|
RU2732416C2 |
| COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | 2012 |
|
RU2606128C2 |
| METHODS AND MATERIALS FOR INCREASING EB TRANSCRIPTION FACTOR POLYPEPTIDE LEVELS | 2020 |
|
RU2838857C2 |
| QUINAZOLINE DERIVATIVES | 2004 |
|
RU2356896C2 |
| COMPOUND AIMED AT PROTEIN AND DEGRADATION THEREOF, AND METHOD FOR PRODUCTION AND USE THEREOF | 2021 |
|
RU2829459C1 |
